Among the most far-reaching strides, nasal vaccination promises to augment
immune responses against numerous pathogens. The present abstract investigates how
nasal vaccination has been able to change the strategies of immunization as well as
pave the way for immune response modulation. In the past, vaccination mainly focused
on systemic immunity through injection-based routes. However, Nasal-Associated
Lymphoid Tissue (NALT), which consists of specialized tissues and abundant immune
cells, offers an exclusive route for both mucosal and systemic immunity induction via
the ventilation channel of our bodies, i.e., the nose. This dual role in immune
stimulation renders nasal vaccination an attractive means to counter various infectious
diseases, such as respiratory viruses like influenza and new pathogens like SARS-Co-
-2. The nasal vaccine has several benefits. One of them is that it is administered
without needles, thus reducing the fear and discomfort connected with injection, which
enhances patient compliance, especially in pediatrics and needle-phobic people.
Secondly, nasal vaccination utilizes local immune responses through a mucosal
immune system where it induces robust secretory IgA antibodies as a first line of
defense against mucosal pathogens. Besides, nasal vaccines may also cause systemic
immunity so that protection is not limited to mucosal surfaces. Nasal vaccines have
been developed into different types, including live attenuated and inactivated vaccines,
as well as newer platforms like subunit vaccines and DNA-based formulations. All
these have their advantages and disadvantages; hence, each pathogen or targeted
population should be dealt with separately. However, nasal vaccination has numerous
challenges to overcome. These include stability, formulating the vaccines into
standardized forms that can be used regularly, and how to regulate these vaccines. It is necessary to address these issues to allow nasal vaccination's maximum utility in public
health intervention. The way forward is ongoing research to improve the formulation of
nasal vaccines, optimize delivery systems, and introduce new adjuvants for better
efficacy against the existing constraints. In addition, personalized medicine can
facilitate the customization of nasal vaccines based on individual immune profiles,
which enhances their effectiveness greatly. Overall, nasal immunization strategies are a
paradigm shift from traditional approaches since they represent a versatile and effective
means of concurrently generating protective immunity against multiple pathogens.
Therefore, exploiting its unique features while addressing current limitations associated
with nasal vaccination can open up new frontiers in modulating immune responses
besides enhancing global health outcomes.
Keywords: Immune response, Mucosal immunity, Needle-free administration, Nasal vaccination, Personalized medicine, Secretory immunoglobulin A (IgA), Vaccine formulations.
